Nivolumab maintains quality of life and reduces symptom deterioration in resectable NSCLC, trial shows
An analysis from the Phase III CheckMate 77T trial confirms that perioperative nivolumab does not compromise health-related quality of life (HRQoL) in patients with resectable non-small cell lung cancer (NSCLC), including ...
Sep 6, 2025
0
14









